{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-013875","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.899879+00:00","generated_at":"2026-05-24T11:28:04.328346+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial","bullets":["High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.","Results from FIGHT DMD trial selected for late-breaking presentation at MDA Clinical & Scientific Conference.","Ifetroban has FDA Orphan Drug and Rare Pediatric Disease Designations for DMD heart disease.","End-of-Phase-2 meeting with FDA planned to discuss next steps for development and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-013875","json":"https://secwatch.observer/filing/0001628280-25-013875.json","markdown":"https://secwatch.observer/filing/0001628280-25-013875.md","text":"https://secwatch.observer/filing/0001628280-25-013875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025013875/0001628280-25-013875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025013875/cpix-20250319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:28:04.328346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}